secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-08-16T23:59:59+00:00
Accession:  0001193125-22-221861
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme upsizes and prices $625M convertible notes due 2028, conversion premium ~30%
--------------------------------------------------------------------------------

- $625M aggregate principal; initial purchasers have option for additional $95M.
- 1.00% annual interest rate; conversion price ~$56.02/share, 30% above $43.09 close.
- Use of proceeds: ~$77.6M to exchange existing 2024 notes, up to $200M for share repurchases, $250M term loan repayment.
- Entered capped call transactions with initial cap price ~$75.41/share to reduce dilution.
- Expects to close offering on August 18, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522221861/0001193125-22-221861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522221861/d335715d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-221861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer